Robert John Ife

This inventor holds 63 USPTO granted patents and 1 published patent application and 1 EPO patent, primarily in Pharmaceutical Compounds (CPC class 5142). Top assignees: Smith Kline & French Laboratories Limited, Smithkline Beecham Corporation, Smithkline Beckman Intercredit B.v.. Active years: 1977-2016.

USPTO Granted Patents = 63 (Patent Applications = 1)

% Patents Active = 87.3

EPO Patents = 1 (Patent Applications = 1)

Average Co-Inventor Count = 2.6

ph-index = 11

Forward Citations = 413(Granted Patents)

Forward Citations (Not Self Cited) = 369(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Stevenage, EN (1977 - 1978)
Aston Brook, GB (1992)
Welwyn, GB (1992 - 1995)
Hertfordshire, GB (1995 - 1999)
Stevenage, GB (1978 - 2007)
Harlow, GB (2003 - 2010)
Essex, GB (2014 - 2016)

Company Filing History:

34 out of 362

Smith Kline & French Laboratories Limited

patents

11 out of 2,198

Smithkline Beecham Corporation

patents

6 out of 6

Smithkline Beckman Intercredit B.v.

patents

4. 6 out of 6

Smithkline Beecham Intercredit B.v.

Boehringer Mannheim Gmbh

patents

8. 1 out of 1

Ilex Oncology Research S.a.

10. 1 out of 834,307

Other

patents

where one patent can have more than one assignee

Years Active: 1977-2016

Loading Chart...

Areas of Expertise:

Pyrimidine Compounds

Aminophosphonic Acids

Quinoline Derivatives

Pyridinone Derivatives

Azetidinone Derivatives

Thienopyrimidines

Biologically Active Compounds

Gastric Acid Secretion

Pharmaceutical Compositions

Substituted Compounds

Gastrointestinal Diseases

Treatment of Atherosclerosis

63 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9266841 - Compounds (2016-02-23),

2. 8871775 - Compounds (2014-10-28),

3. 7652019 - 5,6-trimethylenepyrimidin-4-one compounds (2010-01-26),

4. 7638520 - Pyrimidine compounds (2009-12-29),

5. 7235566 - Pyridinone derivatives for treatment of atherosclerosis (2007-06-26),

6. 7169924 - Pyrimidinone derivatives and their use in the treatment of atherosclerosis (2007-01-30),

7. 7115616 - Pyrimidinone compounds (2006-10-03),

8. 6872711 - β-substituted β-aminoethyl phosphonate derivatives (2005-03-29),

9. 6719520 - Method and compounds (2004-04-13),

10. 6706698 - &agr;-Substituted &bgr;-aminoethyl phosphonate derivatives (2004-03-16),

11. 6660724 - Compounds and pharmaceutical compositions containing them (2003-12-09),

12. 6649619 - Compounds (2003-11-18),

13. 6417192 - Pyrimidinone compounds and pharmaceutical compositions containing them (2002-07-09),

14. 6303784 - Pharmaceutical aminophosphonic acid derivatives (2001-10-16),

15. 6071899 - Azetidinone derivatives for the treatment of atherosclerosis (2000-06-06),

Title: The Innovations of Robert John Ife: A Leader in Pharmaceutical Patents

Introduction: Robert John Ife, based in Stevenage, GB, is a prominent inventor in the pharmaceutical field, holding an impressive total of 63 patents. His innovations focus primarily on compounds that play significant roles in the treatment of various health conditions, particularly cardiovascular diseases.

Latest Patents: Among his noteworthy contributions are the pyrimidone compounds, which are inhibitors of the enzyme Lp-PLA. These compounds demonstrate potential in treating atherosclerosis, showcasing Robert's commitment to advancing medical science and improving patient outcomes through his inventive work.

Career Highlights: Robert has had a distinguished career, working with leading companies in the pharmaceutical industry. Notably, he has held positions at Smith Kline & French Laboratories Limited and SmithKline Beecham Corporation, where he contributed to various projects and innovations that have shaped the landscape of modern medicine.

Collaborations: Throughout his career, Robert worked alongside notable co-inventors such as Thomas H. Brown and Colin A. Leach. These collaborations have proven fruitful, leading to the development of technologies and compounds that address critical health issues, further solidifying Robert's standing in the field of pharmacology.

Conclusion: Robert John Ife's dedication to innovation in the pharmaceutical industry is evident in his extensive patent portfolio. His groundbreaking work on compounds for treating atherosclerosis marks him as a significant figure in the world of invention, inspiring future developments in healthcare and beyond.